Skip to main content
TipRanks
Go Ultimate75% OFF

Recordati Industria Chimica e Farmaceutica SPA (REC) AI Stock Analysis

17 Followers
IT:REC

Recordati Industria Chimica e Farmaceutica SPA

(Milan:REC)

Select Model
Rating:71Outperform
Price Target:EUR 58.00â–²(9.85% Upside)
Action:reiterated
Date:11/13/26

The score is primarily supported by strong, resilient profitability and generally healthy cash generation. It is held back by slower recent revenue growth, meaningful leverage, and weaker near-term technical momentum despite longer-term trend support from the 100- and 200-day averages.

Positive Factors
Strong profitabilityHigh gross, operating, and net margins indicate a profitable pharmaceutical model with meaningful earnings resilience. Sustained margin strength can support internal investment in medicines, commercial infrastructure, and portfolio development while providing protection against moderate revenue fluctuations.
Negative Factors
Slower revenue growthThe sharp slowdown in revenue growth reduces the pace at which Recordati can expand its earnings base and leverage its commercial platform. Even with resilient margins, prolonged low top-line growth could constrain operating leverage and increase reliance on portfolio execution.

Recordati Industria Chimica e Farmaceutica SPA (REC) vs. iShares MSCI Italy ETF (EWI)

-20%-10%0%10%20%30%IT:REC+6.82%EWI+13.72%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 10.90B
Dividend Yield
2.54%
Average Volume (3M)
439.53K
Price to Earnings (P/E)
20.7
Beta (1Y)
0.42
Revenue Growth
8.27%
EPS Growth
30.25%
Country
Italy
Employees
4,693
Sector
Healthcare
Sector Strength
51
Industry
Medical - Pharmaceuticals

Recordati Industria Chimica e Farmaceutica SPA Business Overview & Revenue Model

Company Description

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, researches, develops, produces, and sells pharmaceuticals in Italy, the United States, Spain, France, Germany, Russia, Ukraine, Turkey, Portugal, North Africa, and int...

Recordati Industria Chimica e Farmaceutica SPA Financial Statement Overview

Summary

Strong and consistent profitability (TTM gross margin ~71%, operating margin ~29%, net margin ~18%) supports a high-quality financial profile. Offsetting factors are materially slower TTM revenue growth (~2.2%), meaningful leverage (TTM debt-to-equity ~1.08), and cash-flow conversion that is healthy but not consistently strong (TTM operating cash flow ~46% of EBIT; free cash flow volatility historically).

Income Statement

86Very Positive

Balance Sheet

63Positive

Cash Flow

72Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue2.77B2.62B2.34B2.08B1.85B1.58B
Gross Profit1.97B1.79B1.60B1.42B1.29B1.15B
EBITDA1.02B887.00M795.37M708.16M559.35M578.35M
Net Income524.44M443.62M416.51M389.21M312.34M385.97M
Balance Sheet
Total Assets5.46B5.25B5.13B4.21B4.00B2.82B
Cash, Cash Equivalents and Short-Term Investments503.26M428.82M322.42M221.81M284.73M244.58M
Total Debt2.21B2.47B2.49B1.46B1.72B992.19M
Total Liabilities3.12B3.33B3.26B2.52B2.45B1.43B
Stockholders Equity2.34B1.92B1.88B1.69B1.55B1.38B
Cash Flow
Free Cash Flow604.68M511.77M535.10M102.06M365.35M404.29M
Operating Cash Flow660.61M596.90M569.92M485.32M461.69M491.65M
Investing Cash Flow-149.54M-80.84M-844.94M-379.62M-767.12M-87.50M
Financing Cash Flow-490.10M-407.02M372.11M-168.91M341.28M-355.94M

Recordati Industria Chimica e Farmaceutica SPA Technical Analysis

Technical Analysis SentimentPositive
Last Price52.80

Price Trends

50DMA52.86Negative
100DMA52.43Positive
200DMA50.61Positive

Market Momentum

MACD-0.03Positive
RSI48.06Neutral
STOCH47.92Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:REC, the sentiment is Positive. The current price of 52.80 is below the 20-day moving average (MA) of 52.95, below the 50-day MA of 52.86, and above the 200-day MA of 50.61, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 48.06 is Neutral, neither overbought nor oversold. The STOCH value of 47.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IT:REC.

Recordati Industria Chimica e Farmaceutica SPA Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

IT:REC against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IT:DIAIT:DIA79OutperformEUR 4.38B25.3013.91%1.60%-3.13%-22.16%
IT:RECIT:REC71OutperformEUR 10.90B20.7024.82%2.54%8.27%30.25%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
IT:AMPIT:AMP50NeutralEUR 3.09B37.055.88%2.53%0.18%-36.68%
IT:FDAIT:FDA43NeutralEUR 20.99M-1.08-54.95%―13.94%―

* Healthcare Sector Average

Performance Comparison

-50%0%IT:RECIT:AMPIT:DIAIT:FDADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IT:REC and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IT:RECRecordati Industria Chimica e Farmaceutica SPA52.803.667.46%
IT:AMPAmplifon S.p.A.11.46-1.15-9.13%
IT:DIADiaSorin S.p.A.81.2223.5040.73%
IT:FDAFidia Spa0.02-0.16-91.01%

Recordati Industria Chimica e Farmaceutica SPA Corporate Events

Recordati Publishes Interim Management Report as of September 30, 2026

Nov 11, 2026

Recordati said on November 11, 2026, that its Interim Management Report as of September 30, 2026, had been made available to the public. The report, prepared as additional financial reporting on a voluntary basis and approved by the Board of Director...

Recordati Reports Nine-Month 2026 Revenue and Profit Growth

Nov 10, 2026

Recordati’s consolidated net revenue rose 7.5% to €2,103.7 million in the first nine months of 2026, or 9.4% on a like-for-like, constant-exchange-rate basis; currency movements reduced revenue by €35.6 million. EBITDA increased 7.7% to €801.1 millio...

CVC Investor Purchases Recordati Shares at €53 Each

Nov 9, 2026

On November 9, 2026, CVC Capital Partners IX Aggregator SCA SICAV-RAIF Sub-Fund 2, acting in concert with Respighi BidCo, purchased 64,262 Recordati ordinary shares through J.P. Morgan Securities plc at €53 each, representing approximately 0.031% of...

Respighi BidCo Reports 74.581% Stake in Recordati

Nov 9, 2026

Respighi BidCo purchased 155,966,684 Recordati shares, representing approximately 74.581% of the company’s share capital. The purchases followed the voluntary full takeover offer and included shares tendered by Rossini and shares contributed by the C...

CVC and GBL Contribute 12.428% Recordati Stake to BidCo

Nov 7, 2026

Recordati announced that Respighi BidCo, the vehicle behind its voluntary full public tender offer, executed amended investment and shareholders’ agreements with CVC, GBL and related entities. The agreements refine the parties’ obligations following...

CVC Purchases More Recordati Shares as Offeror Group Reaches 80.8% Stake

Nov 6, 2026

Respighi BidCo’s voluntary full public tender offer for Recordati shares continued on November 6, 2026, with CVC Capital Partners IX Aggregator, acting in concert with the offeror, purchasing 164,420 shares through J.P. Morgan at between €52.95 and €...

CVC Investor Raises Combined Stake in Recordati to 80.723%

Nov 5, 2026

Recordati is a pharmaceutical company focused on specialty and rare-disease medicines, serving international healthcare markets. Its shares are subject to a voluntary total public tender offer by Respighi BidCo, backed by CVC Capital Partners.On 5 No...

Recordati Sells 90,722 Treasury Shares Under Stock Options

Nov 5, 2026

Recordati is an Italian pharmaceutical company; the disclosure does not specify its products or market focus. In October 2026, it sold 90,722 treasury shares directly to beneficiaries of company stock-option plans after they exercised their options,...

CVC Buys 2.526% of Recordati, Raising Combined Stake to 80.713%

Nov 4, 2026

Recordati S.p.A. is the issuer whose ordinary shares are targeted by Respighi BidCo’s voluntary full public tender offer. The release does not provide details on Recordati’s industry, products or market focus.CVC Capital Partners’ investment vehicle...

CVC Investor Raises Concert-Party Stake in Recordati

Nov 3, 2026

Recordati S.p.A. is an international pharmaceutical company focused on specialty medicines and treatments for rare diseases. Its products are marketed across European and international markets, serving patients through prescription healthcare channel...

Respighi BidCo Secures 74.581% of Recordati

Nov 2, 2026

Respighi BidCo completed its voluntary full public tender offer for Recordati, purchasing 155,966,684 shares, or approximately 74.581% of the company’s share capital. The holdings included shares tendered by Rossini and additional shares contributed...

Respighi BidCo Raises Recordati Stake Above 74%

Nov 2, 2026

Recordati S.p.A. is an Italian pharmaceutical company that researches, develops, manufactures and markets prescription medicines, with a focus on rare diseases and specialty-care treatments. Its products are sold internationally, positioning the comp...

CVC-Backed Bidder Tightens Grip on Recordati with Fresh Share Purchases

Oct 29, 2026

Respighi BidCo S.p.A., backed by CVC-related investors, is pursuing a voluntary public tender offer for all ordinary shares of Recordati S.p.A., as part of a broader move to consolidate control of the Italian pharmaceutical group. In the latest step,...

CVC-Backed Investors Tighten Control of Recordati in Ongoing Tender Offer

Oct 28, 2026

The voluntary tender offer for Recordati S.p.A.’s ordinary shares by Respighi BidCo S.p.A. continues to reshape the company’s ownership structure. In the latest move disclosed under Italian market rules, CVC Capital Partners IX Aggregator SCA SICAV-R...

CVC-Led Consortium Tightens Grip on Recordati in Ongoing Tender Offer

Oct 28, 2026

Respighi BidCo S.p.A., backed by investors acting in concert including CVC Investor, Black Mountain S.à r.l. and Rossini S.à r.l., is pursuing a voluntary full public tender offer for Recordati’s ordinary shares. CVC Investor has further strengthened...

CVC-Led Bid Tightens Grip on Recordati With Over 61% Stake Secured

Oct 27, 2026

Respighi BidCo S.p.A., backed by CVC Capital Partners, is pursuing a voluntary takeover bid for all outstanding ordinary shares of Recordati S.p.A., with the offer price set at €53.00 per share following a recent increase. The bid is supported by sev...

Respighi BidCo and Partners Secure Majority Control of Recordati in Tender Offer

Oct 26, 2026

Respighi BidCo S.p.A., backed by investors CVC and GBL, has announced the final results of its voluntary full public tender offer for Recordati S.p.A., securing control of about 74.58% of the company’s share capital through tenders and concerted purc...

Respighi BidCo Moves Toward Majority Control of Recordati After €6.9 Billion Tender

Oct 23, 2026

Respighi BidCo S.p.A. announced the end of the tender period for its voluntary full public tender offer for Recordati’s ordinary shares, following an October increase in the offer price to €53 per share and an extension of the offer window. Based on...

CVC‑Backed Bidder Tightens Grip on Recordati With New Share Purchases

Oct 23, 2026

Respighi BidCo S.p.A., backed by CVC Capital Partners, is pursuing a voluntary public tender offer for all ordinary shares of Italian drugmaker Recordati S.p.A. As part of this process, CVC Capital Partners IX Aggregator SCA SICAV‑RAIF Sub‑Fund 2, ac...

Recordati Director Tenders 30,000 Shares into Respighi Bidco Offer

Oct 23, 2026

Recordati disclosed a transaction by board member Luigi Felice La Corte, who holds a position performing administrative functions as director at the company. The notification, made under EU market abuse rules, relates to dealings in Recordati ordinar...

CVC-Backed Respighi BidCo Tightens Grip on Recordati Ahead of Tender Offer

Oct 22, 2026

Respighi BidCo S.p.A., backed by CVC Capital Partners, is pursuing a voluntary public tender offer for all ordinary shares of Recordati at €53.00 per share, and has stepped up market purchases to support the bid. CVC Investor bought 101,421 shares on...

CVC-Backed Bid Tightens Grip on Recordati as Concert Parties Boost Stakes

Oct 21, 2026

CVC-linked vehicles have been steadily increasing their exposure to Recordati S.p.A., signaling continued financial sponsor interest in the Italian pharma group. Recordati, known for its prescription and specialty medicines, remains a key listed play...

CVC-Backed Bid Vehicle Tightens Grip on Recordati in Ongoing Takeover

Oct 20, 2026

Respighi BidCo S.p.A., backed by CVC funds, is pressing ahead with its voluntary full takeover bid for Recordati S.p.A., as CVC Capital Partners IX Aggregator SCA SICAV-RAIF Sub-Fund 2 expanded its stake through market purchases and a previously agre...

CVC-Backed Respighi BidCo Builds Control in Recordati Through Tender Offer and Additional Share Buys

Oct 19, 2026

Respighi BidCo S.p.A., backed by CVC, is pursuing a voluntary full public tender offer for Recordati’s ordinary shares, with concert-party investor CVC Capital Partners IX Aggregator SCA SICAV-RAIF Sub-Fund 2 buying an additional 144,580 shares at pr...

CVC Steps Up Buying as Tender Offer Tightens Grip on Recordati

Oct 16, 2026

Respighi BidCo S.p.A., backed by CVC, is pursuing a voluntary totalitarian tender offer for all Recordati ordinary shares, with concert parties steadily increasing their exposure at a price of up to €53 per share. On 16 October 2026, CVC Capital Part...

CVC-led Investor Group Tightens Grip on Recordati in Voluntary Takeover

Oct 16, 2026

Respighi BidCo S.p.A., backed by CVC Capital Partners, is pursuing a voluntary full takeover offer for Recordati S.p.A. and has continued to build its position through concert-party purchases. On 16 October 2026, CVC Capital Partners IX Aggregator ac...

CVC Investor Lifts Stake in Recordati as Tender Offer Advances

Oct 15, 2026

Respighi BidCo S.p.A., which has launched a voluntary totalitarian tender offer for Recordati S.p.A., announced that concert party CVC Capital Partners IX Aggregator SCA SICAV-RAIF Sub-Fund 2 has agreed to buy 1,372,657 Recordati shares from vehicles...

CVC-led consortium tightens grip on Recordati amid tender offer

Oct 15, 2026

Respighi BidCo S.p.A. is pursuing a voluntary full public tender offer for all ordinary shares of Recordati, with several CVC-affiliated entities acting in concert to build their position. On 15 October 2026, CVC Capital Partners IX Aggregator SCA SI...

CVC-Backed Respighi BidCo Tightens Grip on Recordati in Ongoing Tender Offer

Oct 15, 2026

Respighi BidCo S.p.A., backed by CVC Capital Partners, is pursuing full control of Recordati through a voluntary public tender offer for all outstanding ordinary shares. The transaction disclosed that CVC Capital Partners IX Aggregator SCA SICAV-RAIF...

CVC-Backed Bid Tightens Grip on Recordati With Fresh Share Purchases

Oct 13, 2026

Respighi BidCo S.p.A., backed by CVC, is pressing ahead with its voluntary takeover offer for Recordati by having CVC Capital Partners IX Aggregator SCA SICAV-RAIF Sub-Fund 2 purchase 339,415 Recordati shares at up to €53.00 each, matching the increa...

CVC-Backed BidCo Tightens Grip on Recordati With Additional Share Purchases

Oct 12, 2026

Respighi BidCo S.p.A., backed by CVC funds, is pursuing a voluntary public tender offer for all ordinary shares of Recordati S.p.A., and a concert party entity has stepped up share purchases in the market. On 12 October 2026, CVC Capital Partners IX...

CVC-Backed BidCo Tightens Control in Recordati Ahead of Voluntary Tender Offer

Oct 9, 2026

Respighi BidCo S.p.A., backed by CVC Capital Partners, is pursuing a voluntary takeover of Recordati and continues to build its position through market purchases aligned with the tender offer. On 9 October 2026, CVC Capital Partners IX Aggregator SCA...

Recordati Director Tenders Shares into Respighi Bidco Offer

Oct 9, 2026

Recordati has disclosed a transaction by director Luigi Felice La Corte, who performs administrative functions within the company. The filing falls under the EU Market Abuse Regulation and concerns dealings in Recordati’s ordinary shares, reflecting...

Recordati Investors Update Terms of Delisting Bid and Investment Agreement

Oct 9, 2026

An investor consortium led by Respighi BidCo S.p.A., together with CVC Capital Partners and GBL, is pursuing a voluntary public tender offer for all ordinary shares of Recordati S.p.A. on Euronext Milan, with the stated goal of delisting the pharmace...

Respighi BidCo Alliance Tightens Grip on Recordati Through Concerted Share Purchases

Oct 8, 2026

Respighi BidCo S.p.A., which has launched a voluntary totalitarian tender offer for all ordinary shares of Recordati, is continuing to consolidate its position through coordinated purchases by parties acting in concert. On 8 October 2026, CVC Capital...

Respighi BidCo Clears Global Regulatory Hurdles for Recordati Takeover

Oct 7, 2026

Respighi BidCo’s voluntary tender offer for all ordinary shares of Recordati has cleared a major regulatory hurdle, with antitrust approvals granted in key jurisdictions including the U.S., EU, China and multiple emerging markets. These authorization...

CVC-Led Consortium Tightens Grip on Recordati in Voluntary Tender Offer

Oct 6, 2026

Respighi BidCo S.p.A., backed by investors including CVC Capital Partners IX Aggregator SCA SICAV-RAIF Sub-Fund 2, is conducting a voluntary public tender offer for all ordinary shares of Recordati S.p.A., with the offer price set at up to €53.00 per...

Respighi BidCo Raises Recordati Tender Offer Price and Extends Acceptance Window

Oct 6, 2026

Respighi BidCo has raised its voluntary tender offer price for all outstanding ordinary shares of Recordati to €53.00 per share, equivalent to €53.71 including the remaining 2025 dividend balance, positioning the bid as a final and fair valuation des...

Recordati Reports September Treasury Share Sales Under Stock Option Plans

Oct 5, 2026

Recordati disclosed a series of transactions in September 2026 involving the sale of treasury shares to beneficiaries of its stock option plans on the Italian market. These transactions followed the exercise of granted options, with the sale price se...

Recordati Chairman Tenders 200,000 Shares Into Respighi Bidco Offer

Sep 10, 2026

Recordati chairman Andrea Recordati, who performs administrative functions as chairman of the board, has carried out a significant transaction involving the company’s ordinary shares. The deal was executed off-market and notified under EU market abus...

Recordati CEO Tenders Shares into Respighi Bidco Takeover Offer

Sep 7, 2026

Recordati has disclosed that Chief Executive Officer Robert Koremans tendered 78,426 Recordati ordinary shares into the voluntary totalitarian tender offer launched by Respighi Bidco S.p.A. The shares were tendered at a price of €51.29 per share in a...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026